Scientists have made a significant advance in the development of a vaccine to combat dog allergies by identifying key molecular candidates in dog allergens that provoke immune responses. This breakthrough represents a critical step toward creating a vaccine effective against many causes of dog allergies.
Read More
Despite numerous studies detailing the characteristics and progression of dog allergies, few have focused on applying this knowledge to create a cure through immune tolerance. For the first time, researchers have pinpointed parts of the molecules that comprise dog allergens, paving the way toward a potential dog allergy vaccine. Their findings were published in the Federation of European Biochemical Societies journal.
Dog allergies are increasingly common globally. Researchers have identified seven different dog allergens, designated Canis familiaris allergens 1 to 7 (Can f 1-7). Notably, Can f 1 is responsible for the majority of allergic reactions, accounting for 50-75% of cases. This allergen is primarily found in a dog's saliva, skin, and tongue tissue.
A focus of ongoing research is the identification of IgE epitopes of Can f 1—specific sequences recognized by the immune system that trigger allergic reactions. Epitopes bind to antigen receptors on immune antibodies, B cells, or T cells. The IgE class of antibodies is particularly important in allergy responses.
In recent years, considerable work has gone into epitope-focused vaccines, including those for dog allergies. Takashi Inui, an allergy research specialist and professor at Osaka Prefecture University, explained that the goal is to present small doses of these epitopes to the immune system, helping it learn to manage them, akin to traditional vaccination strategies. However, he emphasized that identifying the IgE epitope of Can f 1 is essential for progress.
Using X-ray crystallography, researchers have analyzed the structure of the Can f 1 protein, marking a first in this field of study. They observed that, while the protein's folding pattern is similar to other allergens, variations in surface electrical charges suggest specific residues that could serve as candidates for the IgE epitope.
Further research is necessary to refine these candidates, but the initial findings indicate that a hypoallergenic vaccine targeting Can f 1 might soon become feasible. Such a development would not only be groundbreaking in addressing dog allergies but could also have broader implications for allergy treatment in general.
The research, titled “Structure-based prediction of the IgE epitopes of the major dog allergen Can f 1,” was conducted by a team including Masatoshi Nakatsuji, Keisuke Sugiura, and others, and was published on October 26, 2021. DOI: 10.1111/febs.16252.